Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET f... ecancer 6:09 5 years ago 127 Далее Скачать
Targeting RET Alterations With Selective Inhibitor BLU-667 Targeted Oncology 1:22 6 years ago 344 Далее Скачать
Preview: Dr. Gainor on clinical trials American Lung Association 0:20 6 years ago 169 073 Далее Скачать
Preview: Dr. Gainor on lung cancer tumor testing American Lung Association 0:44 6 years ago 187 Далее Скачать
Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors OncLive 1:14 6 years ago 209 Далее Скачать
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers Otolaryngologist,ORL,ENT-Medical Office,Artz Praxis 3:20 6 years ago 37 Далее Скачать
Dr. Gainor on Subgroup Analyses From the PACIFIC Trial in NSCLC OncLive 2:36 5 years ago 69 Далее Скачать
ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen Liu Medicine Matters oncology 3:18 3 years ago 483 Далее Скачать
Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung Cancer OncLive 1:09 4 years ago 111 Далее Скачать
Key Points about RET-positive Lung Cancer American Lung Association 2:10 3 years ago 1 596 Далее Скачать
Dr. Justin Gainor on his ALK-positive Cancer Research Findings ALK Positive 9:37 5 years ago 89 Далее Скачать
How the Treatment Paradigm for EGFR+ Lung Cancer Will Transform Targeted Oncology 2:10 7 years ago 111 Далее Скачать
